Tenon Medical Inc. (NASDAQ: TNON) has regained compliance with Nasdaq’s minimum bid price requirement following a reverse stock split executed last month.
The company, which develops medical devices for sacropelvic disorders and markets two systems for treating the sacroiliac joint, received a deficiency notice from Nasdaq on February 25, 2026 after its shares traded below $1 for 30 consecutive business days. To address the issue, Tenon implemented a 1-for-35 reverse stock split effective August 10, 2026.
After maintaining a closing price of at least $1 for 10 consecutive business days—from August 10 through August 21—the company was notified by Nasdaq Listing Qualifications staff on August 24, 2026 that the compliance matter has been resolved.
Tenon is headquartered in Los Gatos, California, and was incorporated in Delaware in 2012. Its shares trade on the Nasdaq Capital Market under the ticker TNON.
